The ad hoc committee has not had a process over this past year since the shutdown of MAPLE 1 and MAPLE 2. I have before me the draft guidance for maximizing the supply of technetium, and it seems to be based on the Ontario plan. I'm interested in whether there is a sort of single-bank-teller approach to how you would prioritize the patients and mobilize the alternatives. My concern has been that across this country the availability of the alternatives is very different. Could we say that, for example, bone scanning and myocardial perfusion testing are pretty well available across the country right now?
On June 9th, 2009. See this statement in context.